- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05902182
Study to Demonstrate the Efficacy and Safety of Convatec ConvaFoam™ Silicone, ConvaFoam™ Border and ConvaFoam™ Non-adhesive Dressings to Protect Against Skin Breakdown (DONNA)
April 4, 2024 updated by: ConvaTec Inc.
A Prospective, Multi Centre, Interventional, Non-comparator, Open Label Post Market Clinical Follow up Study to Demonstrate the Efficacy and Safety of Convatec ConvaFoam™ Silicone, ConvaFoam™ Border and ConvaFoam™ Non-adhesive Dressings to Protect Against Skin Breakdown
A prospective, multi centre, interventional, non-comparator, open label study to demonstrate the efficacy, safety, and performance of ConvaFoam™ Silicone, ConvaFoam™ Border and ConvaFoam™ Non-adhesive to protect against skin breakdown
Study Overview
Study Type
Interventional
Enrollment (Estimated)
130
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients aged 18 years and over
- Patients able and willing to provide informed consent/Personal Consultee/Nominated consultee/ Their nominated consultee
- Intact healthy skin
- Stage I pressure ulcer/injury
- Patients who are at risk of developing skin breakdown (injury), in any clinical setting, with at least one clinically vulnerable area (including but not limited to sacrum, heel, elbows, hips, ischial tuberosity and spine)
- Braden score of 12 or less
Exclusion Criteria:
- Patients with known allergies to any of the materials used in the dressing
- Subjects requiring any oxidising agents such as hydrogen peroxide or hypochlorite solutions
- Patients who are at high risk of unavoidable skin breakdown for example caused by a medical device (for example, under ventilation or faecal management systems)
- Patients with a wound of any aetiology on the area under investigation Patients who, in the opinion of the investigator, are considered unsuitable for any other reason
- Patients with a history of previous healed pressure ulcer/ injury in the area under investigation
- Patients who demonstrate a deterioration of skin from baseline skin assessment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: ConvaFoam Dressings
All participants skin areas will be assessed and allocated a dressing based upon the investigator's clinical judgement.
They will receive either ConvaFoam Border, Silicone or Non-Adhesive for up to 2 weeks as an addition to their standard pressure injury prevention protocol.
|
ConvaFoam™ Silicone, ConvaFoam™ Border and ConvaFoam™ non-adhesive dressings are designed to provide a moist wound healing environment and removing dead-space between the wound and dressing interface.
These dressings are designed to manage excess exudate levels which may further damage the wound bed and surrounding skin.
In addition, the dressings are designed to protect fragile skin from moisture, shear, and friction damage.
These will be used in line with the patients pressure injury mitigation protocol for a 2 week period, with daily inspections of the skin area.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To measure the efficacy of ConvaFoam™ Silicone, ConvaFoam™ Border and ConvaFoam™ non-adhesive dressings when used to protect of skin against breakdown.
Time Frame: 2 weeks
|
This will be measured by: • The incidence of skin breakdown |
2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To assess the safety of ConvaFoam™ Silicone, ConvaFoam™ Border and ConvaFoam™ non-adhesive dressings when used to protect skin against breakdown.
Time Frame: 2 weeks
|
This will be measured via reporting all device related adverse events and device malfunctions, such as allergic reactions, bleeding, pain/discomfort in area of dressing, skin irritation, and reported as per protocol
|
2 weeks
|
|
To assess the performance of ConvaFoam™ Silicone, ConvaFoam™ Border and ConvaFoam™ non-adhesive dressings when used to protect skin against breakdown.
Time Frame: 2 weeks
|
This will be measured by reporting: The number of times the dressing has been lifted and reapplied before needing to be replaced compared to the instructions for use. The ability of the dressing to be reapplied to the skin following skin assessments as per the patients standard of care. |
2 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
July 1, 2024
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
April 28, 2023
First Submitted That Met QC Criteria
June 5, 2023
First Posted (Actual)
June 13, 2023
Study Record Updates
Last Update Posted (Actual)
April 5, 2024
Last Update Submitted That Met QC Criteria
April 4, 2024
Last Verified
August 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- WC-22-426
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Skin Breakdown
-
University of California, IrvineCompleted
-
University Hospital, Basel, SwitzerlandTerminatedAutophagy | High Enteral Protein Nutrition | Muscle BreakdownSwitzerland
-
Central Finland Hospital DistrictUniversity of Eastern Finland; Tampere University HospitalActive, not recruitingWound Heal | Wound | Skin Wound | Skin Scarring | Wound of Skin | Wound Open | Wound BreakdownFinland
-
CorNeat Vision Ltd.TerminatedGlaucoma Eye | Tissue BreakdownGeorgia
-
CorNeat Vision Ltd.TerminatedGlaucoma Eye | Tissue BreakdownCanada, France, Kenya
-
Apyx MedicalCompletedSkin Laxity | Tissue Breakdown | Collagen Degeneration | Collagen Shrinkage | Tissue DegenerationUnited States
-
Jodi StookeyUniversity of California, Davis; Paracelsus Medical University; University of...Not yet recruitingHealthy | Dysglycemia | Brain Function | Warburg Effect | Thirst; Due to Deprivation of Water | Protein Breakdown | Chronic Underhydration | Aestivation Metabolism | Osmoadaptation
-
University of CalgaryNot yet recruitingBreast Surgery | Surgical Wound | Wound Breakdown | Breast Reduction
-
Bispebjerg HospitalCompletedDiet Modification | Sarcopenia | Protein Intake | Protein Synthesis | Muscle Mass | Protein BreakdownDenmark
Clinical Trials on ConvaFoam
-
ConvaTec Inc.CompletedPressure Injury | Chronic Ulcer of Leg or FootUnited States
-
ConvaTec Inc.CompletedSurgical Wound | Trauma-related WoundUnited States
-
Shih,Wen-ChiNot yet recruitingCABG | Valve Disease, Heart | Aortic Aneurysm | Aortic Diseases | Aortic Dissection | Mitral Disease | AORTIC VALVE DISEASES | Valve Heart Stenosis | CAD - Coronary Artery Disease